Next Article in Journal
An Adjuvanted Inactivated SARS-CoV-2 Microparticulate Vaccine Delivered Using Microneedles Induces a Robust Immune Response in Vaccinated Mice
Next Article in Special Issue
Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans
Previous Article in Journal
Recent Preclinical and Clinical Progress in Liposomal Doxorubicin
Previous Article in Special Issue
Melatonin Mitigates Cisplatin-Induced Ovarian Dysfunction via Altering Steroidogenesis, Inflammation, Apoptosis, Oxidative Stress, and PTEN/PI3K/Akt/mTOR/AMPK Signaling Pathway in Female Rats
 
 
Article
Peer-Review Record

Building a Human Physiologically Based Pharmacokinetic Model for Aflatoxin B1 to Simulate Interactions with Drugs

Pharmaceutics 2023, 15(3), 894; https://doi.org/10.3390/pharmaceutics15030894
by Orphélie Lootens 1,2,3,4,*, Marthe De Boevre 1,3,4, Jia Ning 5, Elke Gasthuys 2, Jan Van Bocxlaer 2, Sarah De Saeger 1,3,4,6 and An Vermeulen 2
Reviewer 2:
Reviewer 3:
Pharmaceutics 2023, 15(3), 894; https://doi.org/10.3390/pharmaceutics15030894
Submission received: 15 February 2023 / Revised: 6 March 2023 / Accepted: 8 March 2023 / Published: 9 March 2023
(This article belongs to the Special Issue Advances in Pharmacokinetics, Pharmacodynamics and Drug Interactions)

Round 1

Reviewer 1 Report

Dear Authors,

Thank you for given opportunity to review this manuscript. Your research deals with the interesting topic of the impact of  aflatoxin and its metabolites on human health, in patient undergoing pharmacotherapy. That was good written article with relevant data and conclusions. 

My main question is: How to apply this findings in everyday clinical practice? What is a clinical meaning of your results? This could be added to conclusion.

I suggest a continuation of research aimed with clear guidelines for physicians and pharmacists.

Sincerely,

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

-The method of data validation is not explained in the manuscript. 

 

-The results from the tables were not discussed very well, as for the reader, it shows that this is more explanation regarding the software simulation capabilities.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 3 Report

The study is relevant and of general interest to the readers of this journal, containing interesting findings relating to aflatoxin B1 and simulated interactions involving the P450 isoforms.

Concerning the main factor of novelty, we can mention the PBPK simulation where is shown that drugs targeting CYP 3A4/1A2 interfere with the PK of aflatoxin B1 and the level of exposure to carcinogenic metabolites.

The introduction presents a well-structured format, perfectly integrating the main issues under study while citing recent bibliography.

We found this article well written, with a good and clear organization of the contents and adequate methodology for drug kinetic modeling and model validation. Only minor comments will be done focusing on the improvement of this subject.

The cited references are recent and appropriate to the discussion.

The availability of data by the authors reflects the clarity and openness desirable in science. We congratulate the authors on this.

Minor comments:

#1_L231-235_Table 5_ The "Mean+/- SD" label (to indicate the uncertainty around the estimated mean) is lacking. Please add the appropriate label.

#2_The Conclusions item is lacking. Please include the Conclusions item.

#3_ L258-268_Table 7_ Please include the precision of the predicted PK values (SD, CV).

 

#4_L353-354_ A “error 404_file not found” appears when we attempt to get the link. Please check this.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Back to TopTop